BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210719
DTEND;VALUE=DATE:20210722
DTSTAMP:20260515T201430
CREATED:20210312T071709Z
LAST-MODIFIED:20210312T071709Z
UID:29322-1626652800-1626911999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Returning digitally in 2021\, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles! \nFocusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation\, this is not one to miss as you seek to accelerate the development of your neurological gene therapy. \nDiscover the latest neurological targets\, familiarise yourself with the European landscape\, and debate and discuss with the leading minds of the field from the likes of UCB\, Lysogene\, UniQure and AskBio\, as they seek to harness the opportunity and move from rare to common disorders such as Alzheimer’s\, Parkinson’s and epilepsy. \n \nFocusing on translation and ‘what’s new’ in the gene therapy for neurological disorders field\, this year’s 3-day agenda has been developed alongside neurological experts from AskBio\, Handl Therapeutics\, Novartis and Spark Therapeutics to capture the most pressing challenges and new opportunities facing the field. \nDiscussing rare to common neurological disorders\, attend the digital meeting in July to: \n\nHear the latest clinical updates from the most advanced companies to inform your future strategies\nDiscover the novel neurological targets being pursued by gene therapy developers to learn of the latest CNS opportunities\nDiscuss how to optimise the use of preclinical models and biomarkers for improved translation and reduced risk to patients\nAsk the European Medicines Agency questions related to the specific regulatory challenges of designing trials for both rare and common disorders\nWeigh up the advantages and disadvantages of established and novel routes of administration for CNS gene therapy delivery\nRaise questions to the neurosurgeons at the forefront of neurosurgical delivery and hear their thoughts on the technical challenges facing different programs\nBe a part of the debate and discussion related to measuring and overcoming CNS immunogenic responses\n\nDon’t miss your opportunity to benchmark against your competitors\, hear the state of the art technology advances and research in the field\, and make new connections at the last digital European meeting\, to revolutionise the development and delivery of your neurological gene therapy.
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-neurological-disorders-europe/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR